| Date | Title | Description |
| 07.06.2023 | Nordic Nanovector – Notice of Annual General Meeting on 28 June 2023 | Nordic Nanovector – Notice of Annual General Meeting on 28 June 2023
Wed, Jun 07, 2023 14:30 CET Report this content
Notice is given that the Annual General Meeting of Nordic Nanovector ASA will be held on 28 June 2023, at 14:00 hours CEST ... |
| 07.06.2023 | Nordic Nanovector – Notice of Annual General Meeting on 28 June 2023 | Nordic Nanovector – Notice of Annual General Meeting on 28 June 2023
Wed, Jun 07, 2023 14:30 CET Report this content
Notice is given that the Annual General Meeting of Nordic Nanovector ASA will be held on 28 June 2023, at 14:00 hours CEST ... |
| 06.06.2023 | Nordic Nanovector announces agreement to acquire Thor Medical, an emerging producer of alpha-emitters for radiopharmaceuticals to treat cancer | Nordic Nanovector announces agreement to acquire Thor Medical, an emerging producer of alpha-emitters for radiopharmaceuticals to treat cancer
Tue, Jun 06, 2023 20:10 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIR... |
| 06.06.2023 | Nordic Nanovector announces agreement to acquire Thor Medical, an emerging producer of alpha-emitters for radiopharmaceuticals to treat cancer | Nordic Nanovector announces agreement to acquire Thor Medical, an emerging producer of alpha-emitters for radiopharmaceuticals to treat cancer
Tue, Jun 06, 2023 20:10 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIR... |
| 18.04.2023 | Nordic Nanovector Publishes Data from the PARADIGME Phase 2 Clinical Trials with Betalutin® on European Clinical Trials Database | Nordic Nanovector Publishes Data from the PARADIGME Phase 2 Clinical Trials with Betalutin® on European Clinical Trials Database
Tue, Apr 18, 2023 11:15 CET Report this content
Oslo, Norway,18 April 2023
Nordic Nanovector ASA (OSE: NANOV) (... |
| 31.03.2023 | NORDIC NANOVECTOR – ANNUAL GENERAL MEETING POSTPONED | NORDIC NANOVECTOR – ANNUAL GENERAL MEETING POSTPONED
Fri, Mar 31, 2023 08:45 CET Report this content
Oslo, Norway, 30 March 2023
The Board of Directors of Nordic Nanovector ASA has decided to postpone the upcoming Annual General Meeting (AG... |
| 23.03.2023 | NORDIC NANOVECTOR – ANNUAL AND REMUNERATION REPORTS APPROVED | NORDIC NANOVECTOR – ANNUAL AND REMUNERATION REPORTS APPROVED
Thu, Mar 23, 2023 11:00 CET Report this content
Oslo, Norway, 23 March 2023
On 22 March 2023, the Board of Directors of Nordic Nanovector ASA approved the Company's financial stat... |
| 28.02.2023 | Nordic Nanovector ASA Results for the Second Half and Full Year 2022 | Nordic Nanovector ASA Results for the Second Half and Full Year 2022
Tue, Feb 28, 2023 07:00 CET Report this content
Oslo, Norway, 28 February 2023
Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company"... |
| 21.02.2023 | Nordic Nanovector ASA: Invitation to Second Half and Full Year 2022 Results Presentation and Webcast | Nordic Nanovector ASA: Invitation to Second Half and Full Year 2022 Results Presentation and Webcast
Tue, Feb 21, 2023 11:00 CET Report this content
Oslo, Norway, 21 February 2023
Nordic Nanovector ASA (OSE: NANOV) announces that it will re... |
| 31.01.2023 | Nordic Nanovector ASA announces that Ludvik Sandnes has been appointed interim Chief Executive Officer (CEO) and Chief Financial Officer (CFO) | Nordic Nanovector ASA announces that Ludvik Sandnes has been appointed interim Chief Executive Officer (CEO) and Chief Financial Officer (CFO)
Tue, Jan 31, 2023 23:15 CET Report this content
Oslo, Norway, 31 January 2023
Nordic Nanovector A... |
| 19.01.2023 | Nordic Nanovector board member resigns | Nordic Nanovector board member resigns
Thu, Jan 19, 2023 20:10 CET Report this content
Oslo, Norway, 19 January 2023
Board member Eddie Berglund has informed the board that he will resign from the board with immediate effect.
For further in... |
| 16.01.2023 | Nordic Nanovector ASA Notes Publication of Letter by Largest Shareholder North Energy | Nordic Nanovector ASA Notes Publication of Letter by Largest Shareholder North Energy
Mon, Jan 16, 2023 22:54 CET Report this content
Oslo, Norway, 16 January 2023
Nordic Nanovector ASA ("Nordic Nanovector" or the "Company&qu... |
| 03.01.2023 | Nordic Nanovector ASA: Extraordinary General Meeting held | Nordic Nanovector ASA: Extraordinary General Meeting held
Tue, Jan 03, 2023 17:59 CET Report this content
Oslo, Norway, 3 January 2023
An Extraordinary General Meeting (the "EGM") of Nordic Nanovector ASA (the "Company")... |
| 13.12.2022 | Nordic Nanovector ASA - Notice of Extraordinary General Meeting on 3 January 2023 | Nordic Nanovector ASA - Notice of Extraordinary General Meeting on 3 January 2023
Tue, Dec 13, 2022 10:47 CET Report this content
Oslo, Norway, 13 December 2022
Nordic Nanovector ASA's ("Nordic Nanovector" or the "Company&quo... |
| 09.12.2022 | Nordic Nanovector update following shareholder vote against proposed merger with APIM Therapeutics | OSLO, Norway, Dec. 9, 2022 /PRNewswire/ -- Nordic Nanovector ASA NANOV ("Nordic Nanovector" or the "Company") today announces an update following the Extraordinary General Meeting held on 1 December at which the proposed... |
| 01.12.2022 | Nordic Nanovector ASA: Extraordinary General Meeting held | Nordic Nanovector ASA: Extraordinary General Meeting held
Thu, Dec 01, 2022 12:23 CET Report this content
Oslo, Norway, 1 December 2022
An Extraordinary General Meeting (the "EGM") of Nordic Nanovector ASA (the "Company"... |
| 25.11.2022 | Nordic Nanovector Launches Dedicated Area on its Website in Norwegian for Information on the Proposed Merger with APIM Therapeutics | Nordic Nanovector Launches Dedicated Area on its Website in Norwegian for Information on the Proposed Merger with APIM Therapeutics
Fri, Nov 25, 2022 12:49 CET Report this content
Oslo, Norway, 25 November 2022
Nordic Nanovector ASA (OSE: N... |
| 23.11.2022 | Nordic Nanovector: Invitation to webcast regarding proposed merger with APIM Therapeutics | Nordic Nanovector: Invitation to webcast regarding proposed merger with APIM Therapeutics
Wed, Nov 23, 2022 07:00 CET Report this content
Oslo, Norway, 23 November 2022
Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or th... |
| 10.11.2022 | Nordic Nanovector ASA - Notice of Extraordinary General Meeting on 1 December 2022 | Nordic Nanovector ASA - Notice of Extraordinary General Meeting on 1 December 2022
Thu, Nov 10, 2022 18:04 CET Report this content
Oslo, Norway, 10 November 2022
Reference is made to the stock exchange announcement by Nordic Nanovector ASA ... |
| 09.11.2022 | Nordic Nanovector and APIM Therapeutics Announce Merger Agreement | Nordic Nanovector and APIM Therapeutics Announce Merger Agreement
Wed, Nov 09, 2022 21:37 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN... |
| 03.11.2022 | Nordic Nanovector Highlights Novel Humanized Anti-CD37 Therapeutic Antibody Candidates for B-cell Malignancies or B-cell-driven Autoimmune Disorders at ASH Annual Meeting | Nordic Nanovector Highlights Novel Humanized Anti-CD37 Therapeutic Antibody Candidates for B-cell Malignancies or B-cell-driven Autoimmune Disorders at ASH Annual Meeting
Thu, Nov 03, 2022 14:01 CET Report this content
Nordic Nanovector Hig... |
| 31.08.2022 | Nordic Nanovector ASA Results for the Second Quarter and First Half 2022 | Nordic Nanovector ASA Results for the Second Quarter and First Half 2022
Wed, Aug 31, 2022 07:00 CET Report this content
Oslo, Norway, 31 August 2022
Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company&quo... |
| 24.08.2022 | Nordic Nanovector ASA: Invitation to Second Quarter and First Half 2022 Results Presentation Webcast | Nordic Nanovector ASA: Invitation to Second Quarter and First Half 2022 Results Presentation Webcast
Wed, Aug 24, 2022 15:31 CET Report this content
Oslo, Norway, 24 August 2022
Nordic Nanovector ASA (OSE: NANOV) announces that it will repo... |
| 18.08.2022 | Nordic Nanovector to explore strategic options | Nordic Nanovector to explore strategic options
Thu, Aug 18, 2022 19:16 CET Report this content
Oslo, Norway, 18 August 2022
Nordic Nanovector ASA (OSE: NANOV) (“Nordic Nanovector” or the “Company”) today announces that its Board of Director... |
| 05.07.2022 | Nordic Nanovector to Discontinue PARADIGME, its Phase 2b Trial with Betalutin[®] in 3L R and R Follicular Lymphoma | Nordic Nanovector to Discontinue PARADIGME, its Phase 2b Trial with Betalutin[®] in 3L R and R Follicular Lymphoma
Tue, Jul 05, 2022 21:26 CET Report this content
Webcast to be held at 08.30 CEST on Wednesday 6 July
Oslo, Norway, 5 July 202... |
| 21.06.2022 | Nordic Nanovector to Seek Regulatory Feedback Following its Preliminary Review and Independent Data Evaluation of PARADIGME, its Phase 2b Trial with Betalutin® in R/R Follicular Lymphoma | Nordic Nanovector to Seek Regulatory Feedback Following its Preliminary Review and Independent Data Evaluation of PARADIGME, its Phase 2b Trial with Betalutin® in R/R Follicular Lymphoma
Tue, Jun 21, 2022 16:31 CET Report this content
Oslo,... |
| 10.06.2022 | Nordic Nanovector Announces that the data from the LYMRIT 37-05 Phase 1 Trial of Betalutin® in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) will be presented at EHA 2022 Meeting | Nordic Nanovector Announces that the data from the LYMRIT 37-05 Phase 1 Trial of Betalutin® in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) will be presented at EHA 2022 Meeting
Fri, Jun 10, 2022 10:13 CET Report this content
O... |
| 02.06.2022 | Nordic Nanovector to Conduct a Comprehensive Review and Independent Data Evaluation of PARADIGME, its Phase 2b Trial with Betalutin® in R/R FL as a Result of Continuing Slow Recruitment | Nordic Nanovector to Conduct a Comprehensive Review and Independent Data Evaluation of PARADIGME, its Phase 2b Trial with Betalutin® in R/R FL as a Result of Continuing Slow Recruitment
Thu, Jun 02, 2022 07:00 CET Report this content
Oslo, ... |
| 20.05.2022 | Nordic Nanovector ASA: Allocation of restricted stock units (RSUs) to the board of directors | Nordic Nanovector ASA: Allocation of restricted stock units (RSUs) to the board of directors
Fri, May 20, 2022 09:58 CET Report this content
Oslo, Norway, 20 May 2022
Reference is made to the minutes from Nordic Nanovector ASA's (the "... |
| 13.05.2022 | Nordic Nanovector ASA: Results for the First Quarter 2022 | Nordic Nanovector ASA: Results for the First Quarter 2022
Fri, May 13, 2022 07:00 CET Report this content Oslo, Norway, 13 May 2022
Nordic Nanovector ASA (OSE: NANOV) announces its results for the first quarter 2022. A presentation by Nordi... |
| 06.05.2022 | Nordic Nanovector ASA: Invitation to First Quarter 2022 Results Presentation and Webcast | Nordic Nanovector ASA: Invitation to First Quarter 2022 Results Presentation and Webcast
Fri, May 06, 2022 15:35 CET Report this content
Oslo, Norway, 6 May 2022
Nordic Nanovector ASA (OSE: NANOV) announces that it will report its results f... |
| 03.05.2022 | Nordic Nanovector: New Publication Highlights Synergistic Potential of CD37-targeted Radioimmunoconjugate Humalutin® in Combination with the PARP-inhibitor Olaparib | Nordic Nanovector: New Publication Highlights Synergistic Potential of CD37-targeted Radioimmunoconjugate Humalutin® in Combination with the PARP-inhibitor Olaparib
Tue, May 03, 2022 08:47 CET Report this content
Second publication reports ... |
| 28.04.2022 | Nordic Nanovector ASA: The Annual General Meeting held | Nordic Nanovector ASA: The Annual General Meeting held
Thu, Apr 28, 2022 17:11 CET Report this content
Oslo, Norway, 28 April 2022
The Annual General Meeting (the “AGM”) of Nordic Nanovector ASA (the "Company") (OSE: NANOV) was he... |
| 06.04.2022 | Nordic Nanovector ASA Announces Proposed Board Changes – Former Algeta CEO Thomas Ramdahl nominated to Join Board of Directors | Oslo, Norway, 6 April 2022
Nordic Nanovector ASA (OSE: NANOV) announces that its Nomination Committee has nominated Dr Thomas Ramdahl for election as a Non-executive Director at the Company’s Annual General Meeting (AGM) on 28 April 2022.
... |
| 06.04.2022 | Nordic Nanovector ASA publishes Annual Report 2021 | Nordic Nanovector ASA publishes Annual Report 2021
Wed, Apr 06, 2022 11:00 CET Report this content
Oslo, Norway, 6 April 2022
On 5 April 2022, the Board of Directors of Nordic Nanovector ASA approved the Company's financial statements for 2... |
| 06.04.2022 | Nordic Nanovector ASA Announces Proposed Board Changes – Former Algeta CEO Thomas Ramdahl nominated to Join Board of Directors | Nordic Nanovector ASA Announces Proposed Board Changes – Former Algeta CEO Thomas Ramdahl nominated to Join Board of Directors
Wed, Apr 06, 2022 08:41 CET Report this content
Oslo, Norway, 6 April 2022
Nordic Nanovector ASA (OSE: NANOV) ann... |
| 06.04.2022 | Nordic Nanovector ASA – Notice of Annual General Meeting on 28 April 2022 | Nordic Nanovector ASA – Notice of Annual General Meeting on 28 April 2022
Wed, Apr 06, 2022 11:31 CET Report this content
Oslo, Norway, 6 April 2022
Notice is given that the Annual General Meeting of Nordic Nanovector ASA will be held on 28... |
| 14.03.2022 | Nordic Nanovector ASA - Final results of the subsequent offering | Nordic Nanovector ASA - Final results of the subsequent offering
Mon, Mar 14, 2022 10:08 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIV... |
| 11.03.2022 | Nordic Nanovector ASA - Preliminary results of the subsequent offering | Nordic Nanovector ASA - Preliminary results of the subsequent offering
Fri, Mar 11, 2022 19:01 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINIS... |
| 09.03.2022 | Nordic Nanovector Announces Presentation of Preclinical Data on Alpha37, at the American Association for Cancer Research 2022 Annual Meeting | Nordic Nanovector Announces Presentation of Preclinical Data on Alpha37, at the American Association for Cancer Research 2022 Annual Meeting
Wed, Mar 09, 2022 07:30 CET Report this content
Oslo, Norway, 9 March 2022
Nordic Nanovector ASA (O... |
| 01.03.2022 | Nordic Nanovector ASA: Results for the Fourth Quarter and Full Year 2021 | Nordic Nanovector ASA: Results for the Fourth Quarter and Full Year 2021
Tue, Mar 01, 2022 07:01 CET Report this content
Oslo, Norway, 01 March 2022
Nordic Nanovector ASA (OSE: NANOV) announces its results for the fourth quarter and full ye... |
| 28.02.2022 | Nordic Nanovector ASA - Commencement of the subscription period in the subsequent share offering | Nordic Nanovector ASA - Commencement of the subscription period in the subsequent share offering
Mon, Feb 28, 2022 08:00 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE... |
| 24.02.2022 | Nordic Nanovector ASA: Prospectus approved | Nordic Nanovector ASA: Prospectus approved
Thu, Feb 24, 2022 14:11 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE... |
| 24.02.2022 | Nordic Nanovector ASA - Resolution to increase the share capital in connection with the subsequent offering and terms of the subsequent offering | Nordic Nanovector ASA - Resolution to increase the share capital in connection with the subsequent offering and terms of the subsequent offering
Thu, Feb 24, 2022 12:00 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, D... |
| 22.02.2022 | Nordic Nanovector ASA: Invitation to Fourth Quarter and Full Year 2021 Results Presentation and Webcast | Nordic Nanovector ASA: Invitation to Fourth Quarter and Full Year 2021 Results Presentation and Webcast
Tue, Feb 22, 2022 09:57 CET Report this content
Oslo, Norway, 22 February 2022
Nordic Nanovector ASA (OSE: NANOV) announces that it will... |
| 14.02.2022 | Nordic Nanovector ASA: Extraordinary general meeting held | Nordic Nanovector ASA: Extraordinary general meeting held
Mon, Feb 14, 2022 10:12 CET Report this content
Oslo, Norway, 14 February 2022
Nordic Nanovector ASA (the "Company") announces that an extraordinary general meeting (“EGM”)... |
| 24.01.2022 | Nordic Nanovector ASA - Notice of extraordinary general meeting | Nordic Nanovector ASA - Notice of extraordinary general meeting Mon, Jan 24, 2022 16:45 CET
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPL... |
| 20.01.2022 | Nordic Nanovector ASA – Private placement of new shares successfully placed | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA, NEW ZEALAND, JAPAN OR THE UNITED STATES, OR ANY OTHER J... |
| 20.01.2022 | Nordic Nanovector ASA - Ex subsequent offering today | Nordic Nanovector ASA - Ex subsequent offering today Thu, Jan 20, 2022 07:00 CET
Oslo, Norway, 20 January 2022
Reference is made to the announcement by Nordic Nanovector ASA (OSE: NANO) on 19 January 2022 and that the company is considering... |
| 19.01.2022 | Nordic Nanovector ASA – Contemplated private placement of new shares | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA, NEW ZEALAND, JAPAN OR THE UNITED STATES, OR ANY OTHER J... |
| 19.01.2022 | Nordic Nanovector ASA - Key information regarding potential subsequent offering | Nordic Nanovector ASA - Key information regarding potential subsequent offering Wed, Jan 19, 2022 22:22 CET
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN
AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REG... |
| 12.01.2022 | Nordic Nanovector ASA: Annual General Meeting held | Source: Nordic Nanovector |
| 12.01.2022 | Nordic Nanovector R&D Day: Building Value from Betalutin® and a pipeline of broader therapeutic opportunities targeting CD37 | Oslo, Norway, 30 November 2021
Nordic Nanovector ASA (OSE: NANOV), a clinical-stage biotech company focused on CD37-targeted therapies for haematological cancers and immune diseases, will today host an R&D day starting at 14:00 CET/ 13... |
| 07.01.2022 | Nordic Nanovector Provides update on PARADIGME, its Phase 2b Pivotal Trial with Betalutin® in R/R Follicular Lymphoma | Nordic Nanovector Provides update on PARADIGME, its Phase 2b Pivotal Trial with Betalutin® in R/R Follicular Lymphoma Fri, Jan 07, 2022 19:22 CET
Oslo, Norway, 7 January 2022
Nordic Nanovector ASA (OSE: NANOV) provides an update on the time... |
| 16.12.2021 | Nordic Nanovector appoints Experienced International Life Sciences Executive Sandra Jonsson as Chief Operating Officer | Nordic Nanovector appoints Experienced International Life Sciences Executive Sandra Jonsson as Chief Operating Officer Thu, Dec 16, 2021 07:30 CET
Oslo, Norway, 16 December 2021
Nordic Nanovector ASA (OSE: NANOV), a clinical-stage biotech c... |
| 08.12.2021 | Nordic Nanovector to Present at DNB's 12[th] Nordic Healthcare Conference | Nordic Nanovector to Present at DNB's 12[th] Nordic Healthcare Conference Wed, Dec 08, 2021 16:30 CET
Oslo, Norway, 8 December 2021
Nordic Nanovector ASA (OSE: NANOV), clinical-stage biotech company focused on CD37-targeted therapies for ha... |
| 07.12.2021 | Nordic Nanovector to present at 3rd Targeted Radiopharmaceutical Summit 2021 | Nordic Nanovector to present at 3rd Targeted Radiopharmaceutical Summit 2021 Tue, Dec 07, 2021 07:30 CET
Oslo, Norway, 7 December 2021
Nordic Nanovector ASA (OSE: NANOV), a clinical-stage biotech company focused on CD37-targeted therapies f... |
| 30.11.2021 | Nordic Nanovector R&D Day: Building Value from Betalutin® and a pipeline of broader therapeutic opportunities targeting CD37 | Nordic Nanovector R&D Day: Building Value from Betalutin® and a pipeline of broader therapeutic opportunities targeting CD37 Tue, Nov 30, 2021 07:00 CET
Oslo, Norway, 30 November 2021
Nordic Nanovector ASA (OSE: NANOV), a clinical-stage... |
| 29.11.2021 | Nordic Nanovector ASA: R&D Day to be virtual via live webcast only | Nordic Nanovector ASA: R&D Day to be virtual via live webcast only Mon, Nov 29, 2021 08:00 CET
Oslo, Norway, 29 November 2021
Nordic Nanovector ASA (OSE: NANOV), a clinical stage biotechnology company developing targeted radiopharmaceut... |
| 18.11.2021 | Nordic Nanovector ASA: Results for the Third Quarter 2021 | Nordic Nanovector ASA: Results for the Third Quarter 2021 Thu, Nov 18, 2021 07:01 CET Oslo, Norway, 18 November 2021
Nordic Nanovector ASA (OSE: NANOV) announces its results for the third quarter 2021. A presentation by Nordic Nanovector’s ... |
| 18.11.2021 | Nordic Nanovector ASA: Invitation to attend R&D Day | Nordic Nanovector ASA: Invitation to attend R&D Day Thu, Nov 18, 2021 07:04 CET
Oslo, Norway, 18 November 2021
Nordic Nanovector ASA (OSE: NANOV), a clinical stage biotechnology company developing targeted radiopharmaceuticals to extend... |
| 18.11.2021 | Correction: Nordic Nanovector ASA: Invitation to attend R&D Day – clarification of CMO title | Correction: Nordic Nanovector ASA: Invitation to attend R&D Day – clarification of CMO title Thu, Nov 18, 2021 11:26 CET
Oslo, Norway, 18 November 2021
Nordic Nanovector ASA (OSE: NANOV), a clinical stage biotechnology company developin... |
| 12.11.2021 | Nordic Nanovector ASA: Invitation to Third Quarter 2021 Results Presentation and Webcast | Nordic Nanovector ASA: Invitation to Third Quarter 2021 Results Presentation and Webcast Fri, Nov 12, 2021 10:30 CET Oslo, Norway, 12 November 2021
Nordic Nanovector ASA (OSE: NANOV) announces that it will report its results for the third q... |
| 09.11.2021 | Nordic Nanovector supports The Health Policy Partnership’s initiative to improve appropriate readiness for radioligand therapy (radioimmunotherapy) in lymphoma | Nordic Nanovector supports The Health Policy Partnership’s initiative to improve appropriate readiness for radioligand therapy (radioimmunotherapy) in lymphoma Tue, Nov 09, 2021 17:54 CET
Abstract by The Health Policy Partnership entitled “... |
| 08.11.2021 | Nordic Nanovector appoints experienced biotech executive Pierre Dodion MD as Chief Medical Officer | Nordic Nanovector appoints experienced biotech executive Pierre Dodion MD as Chief Medical Officer Mon, Nov 08, 2021 18:20 CET
Oslo, Norway, 8 November 2021
Nordic Nanovector ASA (OSE: NANO) announces the appointment of Pierre Dodion MD as ... |
| 04.11.2021 | Save the Date: Nordic Nanovector ASA to host in-person and virtual R&D Day on 30 November 2021 | Save the Date: Nordic Nanovector ASA to host in-person and virtual R&D Day on 30 November 2021 Thu, Nov 04, 2021 07:30 CET
Oslo, Norway, 4 November 2021
Nordic Nanovector ASA (OSE: NANOV), a clinical stage biotechnology company developi... |
| 19.10.2021 | Nordic Nanovector enters research collaboration with the University of Pennsylvania to generate a novel CD37-targeting CAR-T cell approach | Nordic Nanovector enters research collaboration with the University of Pennsylvania to generate a novel CD37-targeting CAR-T cell approach Tue, Oct 19, 2021 07:00 CET
Oslo, Norway, 19 October 2021
Nordic Nanovector ASA (OSE: NANOV) is pleas... |
| 27.08.2021 | Nordic Nanovector ASA: Results for the Second Quarter and First Half 2021 | Nordic Nanovector ASA: Results for the Second Quarter and First Half 2021 Fri, Aug 27, 2021 07:01 CET Oslo, Norway, 27 August 2021
Nordic Nanovector ASA (OSE: NANOV) announces its results for the second quarter and first half 2021. A presen... |
| 20.08.2021 | Nordic Nanovector ASA: Invitation to Second Quarter and First Half 2021 Results Presentation Webcast | Nordic Nanovector ASA: Invitation to Second Quarter and First Half 2021 Results Presentation Webcast Fri, Aug 20, 2021 08:00 CET Oslo, Norway, 20 August 2021
Nordic Nanovector ASA (OSE: NANOV) announces that it will report its results for t... |
| 03.08.2021 | Nordic Nanovector Provides Update on PARADIGME, its Phase 2b Pivotal Trial with Betalutin® in R/R Follicular Lymphoma | Nordic Nanovector Provides Update on PARADIGME, its Phase 2b Pivotal Trial with Betalutin® in R/R Follicular Lymphoma Tue, Aug 03, 2021 23:11 CET
Oslo, Norway, 3 August 2021
Nordic Nanovector ASA (OSE: NANOV) provides an update on the timel... |
| 02.06.2021 | Nordic Nanovector ASA: Allocation of restricted stock units (RSUs) to the board of directors | Nordic Nanovector ASA: Allocation of restricted stock units (RSUs) to the board of directors Wed, Jun 02, 2021 07:00 CET
Oslo, Norway, 2 June 2021
Reference is made to the minutes from Nordic Nanovector ASA's (the "Company") (OSE:... |
| 26.05.2021 | Nordic Nanovector ASA: Results for the First Quarter 2021 | Nordic Nanovector ASA: Results for the First Quarter 2021 Wed, May 26, 2021 07:01 CET
Oslo, Norway, 26 May 2021
Nordic Nanovector ASA (OSE: NANOV) announces its results for the first quarter 2021. A live webcast presentation by Nordic Nanov... |
| 26.05.2021 | Nordic Nanovector ASA: Resultat for første kvartal 2021 | Nordic Nanovector ASA: Resultat for første kvartal 2021 Wed, May 26, 2021 07:00 CET
Oslo, 26. mai 2021
Nordic Nanovector ASA (OSE: NANOV) publiserer i dag resultatene for første kvartal 2021. Selskapets ledelse vil presentere resultatene i ... |
| 20.05.2021 | Nordic Nanovector ASA: Invitation to First Quarter 2021 Results Presentation and Webcast | Nordic Nanovector ASA: Invitation to First Quarter 2021 Results Presentation and Webcast Thu, May 20, 2021 08:00 CET
Oslo, Norway, 20 May 2021
Nordic Nanovector ASA (OSE: NANOV) announces that it will report its results for the first quarte... |
| 08.05.2020 | Ex-AstraZeneca exec Kristen Buck hops aboard Icon as CMO; Immunocore taps Brian DiDonato as CFO | Kristen Buck
→ Prominent CRO player Icon is bolstering its leadership, with Kristen Buck taking the reins as CMO.
For slightly more than a year and a half, Buck was the SVP & chief of clinical development at Optum, part ... |
| 07.12.2016 | Nordic Nanovector bags $60M for Rituxan combo phase 2 | Nordic Nanovector has raised NOK 499 million ($60 million) in an oversubscribed private placement. The cash injection will enable Nanovector to test its CD37-targeting antibody-radionuclide conjugate (ARC) in combination with rituximab, bet... |
| - | NORDIC NANOVECTOR TO HOST CAPITAL MARKETS DAY IN OSLO ON 22 NOVEMBER 2017 | Oslo, Norway, 14 August 2017
Nordic Nanovector ASA (OSE: NANO), a biopharmaceutical company focusing on the development and commercialisation of novel targeted therapeutics for
haematological cancers, will host a capital markets day on 22... |
| - | NORDIC NANOVECTOR: RESULTS FOR THE THIRD QUARTER AND FIRST NINE MONTHS OF 2015 | Oslo, Norway, 21 October 2015
Nordic Nanovector ASA (OSE: NANO), a company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology, announces its results for the third quarter and first ... |
| - | UPDATED RESULTS OF ONGOING PHASE 1/2 STUDY WITH BETALUTIN™ IN RELAPSED CD37+ NON-HODGKIN LYMPHOMA PATIENTS | UPDATED RESULTS SHOW SUSTAINED EFFICACY AND CONFIRM FAVOURABLE SAFETY PROFILE
Oslo, Norway, 17 June 2015: Nordic Nanovector ASA (OSE: NANO), a company focusing on the development and commercialization of novel targeted therapeutics in haem... |
| - | Nordic Nanovector ASA applies for listing of its shares on the Oslo Stock Exchange |
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE S... |
| - | Nordic Nanovector ASA – Results for the First Quarter 2019 | Source: Nordic Nanovector |
| - | Nordic Nanovector to Present at Biotech Showcase 2017 | Oslo, Norway, 4 January 2017
Nordic Nanovector ASA (OSE: NANO), a biotechnology company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology, announces today that Chief Operating Offi... |
| - | Nordic Nanovector ASA – Results for the Third Quarter 2019 | Source: Nordic Nanovector |
| - | Nordic Nanovector – Private placement successfully completed | Not for release, publication or distribution, directly or indirectly, in the United States of America, Canada, Japan or Australia
Oslo, Norway, 7 December 2016
Reference is made to the stock exchange release from Nordic Nanovector ASA (OS... |
| - | NORDIC NANOVECTOR PRESENTS PRECLINICAL RESEARCH WITH BETALUTIN® SHOWING POTENTIAL FOR COMBINATION WITH RITUXIMAB IN NON-HODGKIN LYMPHOMA | Poster Presented at the 57th American Society of Hematology Annual Meeting
Oslo, Norway, 7 December 2015
Nordic Nanovector ASA’s (OSE: NANO) poster describing preclinical research with Betalutin® (177Lu-HH1) was presented at the 57th Annu... |
| - | Nordic Nanovector ASA – Key information regarding potential repair offering | Not for release, publication or distribution, directly or indirectly, in the United States of America, Canada, Japan or Australia
THIS IS A RESTRICTED COMMUNICATION AND YOU MUST NOT FORWARD IT OR ITS CONTENTS TO ANY PERSON TO WHOM FORWARDI... |
| - | Updated results from Phase 1/2 trial of Betalutin® in non-Hodgkin lymphoma to be presented at ASH annual meeting in December | Oslo, Norway, 3 November 2016
Nordic Nanovector ASA (OSE: NANO) announces that updated results and analysis from its ongoing Phase 1/2 clinical trial of Betalutin® (177Lu-satetraxetan-lilotomab) in subjects with relapsed/refractory non-Hod... |
| - | Accepted abstract by ICML with updated results from Phase 1/2 trial of Betalutin® in NHL is now available on-line | Oslo, Norway, 7 June 2017
Nordic Nanovector ASA (OSE: NANO) announces that an abstract reporting updated results from the ongoing LYMRIT 37-01 Phase 1/2 clinical study of Betalutin® (177Lu-satetraxetan-lilotomab) in patients with relapsed/... |
| - | Nordic Nanovector Appoints Experienced Pharmaceutical Business Leader Erik Skullerud as Chief Executive Officer | Nordic Nanovector ASA (OSE: NANOV) announces the appointment of Erik Skullerud as Chief Executive Officer (CEO). He will take up the position on 20 September 2021 and will be based in the company’s office in Zug, Switzerland, splitting his ... |
| - | RESULTS OF PHASE 1 STUDY OF BETALUTIN™ IN PATIENTS WITH NON-HODGKIN LYMPHOMA TO BE PRESENTED AT THE INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA | Oslo, Norway, 23 April 2015: Nordic Nanovector ASA (OSE: NANO), a company focusing on the development and commercialization of novel targeted therapeutics in haematology and oncology, announces that results of its Phase 1 clinical study of ... |
| - | Nordic Nanovector ASA – Results for the Second Quarter and First Half 2019 | Source: Nordic Nanovector |
| - | NORDIC NANOVECTOR – INCREASE IN OFFERING SIZE AND NARROWING OF THE INDICATIVE PRICE RANGE | NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE... |
| - | Nordic Nanovector ASA – Final results of the subsequent offering | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA, NEW ZEALAND, JAPAN OR THE UNITED STATES, OR ANY OTHER J... |
| - | NORDIC NANOVECTOR ANNOUNCES RESIGNATION OF CHIEF MEDICAL OFFICER | NORDIC NANOVECTOR ANNOUNCES RESIGNATION OF CHIEF MEDICAL OFFICER | Nordicnanovector
Source: Nordic Nanovector
|
| - | Nordic Nanovector ASA – Results for third quarter 2016 | All operations advancing according to schedule
Oslo, Norway, 23 November 2016
Nordic Nanovector ASA (OSE: NANO) announces its results for the third quarter 2016. A presentation of the results by the company’s senior management team will t... |
| - | Nordic Nanovector’s Betalutin® Receives Fast-Track Designation from US FDA for Marginal Zone Lymphoma | Oslo, Norway, 29 June 2020
Nordic Nanovector ASA (OSE: NANO) today announces that the US Food and Drug Administration (FDA) has granted Fast Track designation for investigating Betalutin® (177Lu lilotomab satetraxetan) for the treatment of... |
| - | Nordic Nanovector ASA: Results for the Third Quarter 2018 | Oslo, Norway, 6 November 2018
Nordic Nanovector ASA (OSE: NANO) announces its third quarter 2018 results today. A presentation by the company’s senior management team will take place today in Oslo at 08:30 CET, see details below.
Eduardo ... |
| - | Nordic Nanovector ASA – Results for Fourth Quarter and Full Year 2016 | A year of significant progress with operations on track, new projects to initiate in 2017
Press Release 6/2017.
See : Q416 report 2016
See : Q4 16 presentation 2016
Source: Nordic Nanovector |
| - | Nordic Nanovector adapts clinical development plan for Betalutin® in Follicular Lymphoma | Oslo, Norway, 15 October 2015
Nordic Nanovector ASA (OSE: NANO), a company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology, announces that it has taken the decision to revise its... |
| - | Nordic Nanovector ASA: Annual General Meeting held | Oslo, Norway, 28 April 2021
The Annual General Meeting of Nordic Nanovector ASA (the “Company”) (OSE: NANOV) was held today on 28 April 2021 in Oslo, Norway.
All proposals were resolved by the Annual General Meeting as presented in the no... |